Table 1.

Baseline characteristics of participants enrolled in the vanguard phase of a clinical trial evaluating nephrologist follow-up versus usual care after a hospitalization with AKI

CharacteristicsAKI Follow-Up Clinic (n=34)Usual Care (n=37)
Demographics
 Age (years), mean (SD)64 (10)67 (12)
 Female, n (%)10 (29)12 (32)
 Baseline serum creatinine (mg/dl), mean (SD)0.98 (0.35)1.01 (0.32)
 Baseline eGFR (ml/min per 1.73 m2), mean (SD)79 (23)73 (22)
Comorbidities, n (%)
 Diabetes14 (41)17 (46)
 Heart failure6 (18)11 (30)
 Coronary artery disease11 (32)9 (24)
 Hypertension19 (56)29 (78)
 Cancer9 (26)12 (32)
Preadmission medications, n (%)
 ACEi or ARB20 (59)23 (62)
 Statin20 (59)21 (57)
β-Blocker12 (35)15 (40)
 Calcium channel blocker5 (15)12 (32)
 Loop diuretic4 (12)10 (27)
 Thiazide diuretic8 (24)5 (14)
 Metformin12 (35)11 (30)
 NSAIDs5 (15)4 (11)
 Total no. of medications, mean (SD)5.7 (3.4)6.4 (3.8)
Details of hospitalization
 Intensive care unit, n (%)15 (44)18 (49)
 Mechanical ventilation, n (%)10 (29)13 (32)
 Admitted to surgical service, n (%)8 (24)11 (30)
 Length of stay (days), median (IQR)11 (7–19)16 (10–22)
 KDIGO AKI stage 2, n (%)11 (32)17 (46)
 KDIGO AKI stage 3, n (%)23 (68)20 (54)
 Dialysis, n (%)2 (6)3 (8)
 Discharge serum creatinine (mg/dl), mean (SD)1.48 (0.75)1.40 (0.71)
 Discharge eGFR (ml/min per 1.73 m2), mean (SD)55 (23)59 (27)
 Discharge serum creatinine >50% of pre-AKI baseline, n (%)17 (50)13 (35)
  • ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; NSAID, nonsteroidal anti-inflammatory drug; IQR, interquartile range; KDIGO, Kidney Disease Improving Global Outcomes.